Show simple item record

dc.contributor.authorBedford, Theresa
dc.contributor.authorKisaalita, Nkaku
dc.contributor.authorHaycock, Nathaniel R
dc.contributor.authorMullins, C Daniel
dc.contributor.authorWright, Thelma
dc.contributor.authorCuratolo, Michele
dc.contributor.authorHamlin, Lynette
dc.contributor.authorColloca, Luana
dc.date.accessioned2022-04-13T12:41:03Z
dc.date.available2022-04-13T12:41:03Z
dc.date.issued2022-03-24
dc.identifier.issn1664-0640
dc.identifier.urihttp://hdl.handle.net/10713/18557
dc.description.abstractStandard opioid tapers tend to be associated with increased patient anxiety and higher pain ratings. Pre-authorized concealed opioid reductions may minimize expectations such as fear of increased pain due to the reduction of opioids and, prolong analgesic benefits in experimental settings. We recently observed that patients and clinicians are open to concealed opioid tapering. However, little is known about the "why" behind their attitudes. Based on this lack of data, we analyzed qualitative responses to survey questions on patients' and clinicians' acceptance of a concealed opioid reduction for chronic pain. Seventy-four patients with a history of high dose opioid therapy and 49 clinicians completed a web-based questionnaire with open-ended questions examining responses to two hypothetical clinical trials comparing a concealed opioid reduction pre-authorized by patients vs. standard tapering. We used content analysis based on qualitative descriptive methodology to analyze comments from the patients and clinicians. Five themes were identified: informed consent; anxiety; safety; support; and ignorance is bliss, or not. These themes highlight the overall positive attitudes toward concealed opioid tapers. Our findings reinforce the importance of patient-centered care and are expected to inform the design of clinical trials from both the patient and clinician perspective. This qualitative study presents patients' and clinicians' attitudes toward hypothetical scenarios for a trial of pre-authorized reduction of opioids. The findings indicate positive attitudes and the relevance of engaging patients with effective decision-making processes.en_US
dc.description.urihttps://doi.org/10.3389/fpsyt.2022.820357en_US
dc.language.isoenen_US
dc.rightsCopyright © 2022 Bedford, Kisaalita, Haycock, Mullins, Wright, Curatolo, Hamlin and Colloca.en_US
dc.subjectchronic painen_US
dc.subjectconcealed (hidden) administrationen_US
dc.subjectopioid taperingen_US
dc.subjectplacebo effectsen_US
dc.subjectqualitative descriptiveen_US
dc.titleAttitudes Toward a Pre-authorized Concealed Opioid Taper: A Qualitative Analysis of Patient and Clinician Perspectives.en_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fpsyt.2022.820357
dc.identifier.pmid35401245
dc.source.journaltitleFrontiers in psychiatry
dc.source.volume13
dc.source.beginpage820357
dc.source.endpage
dc.source.countrySwitzerland
dc.identifier.journalFrontiers in psychiatry


This item appears in the following Collection(s)

Show simple item record